The New Fat-Busting Injection: Weight Loss Of ‘A Stone’ In Merely Twenty Weeks

Scientists have vouched for the efficacy of the anti-obesity shot to surpass that of the presently available fat reduction pills by twofold. Few of the patients that were administered the anti-fat shot – liraglutide, had weight loss of more than a stone in twenty weeks.

The drug is also believed to lower blood pressure and helped gain better control over glucose levels among prediabetes patients – a precursor to diabetes. Liraglutide, available by the product name ‘Victoza’, has obtained license for prescription usage among overweight patients in Britain from July onwards.

During the course of the newest study, 564 entrants were administered either the daily, single-shot, liraglutide doses that ranged from 1.2mg- 3.0mg or the thrice-a-day orlistat pills – another flab-fighting treatment.

All the candidates for the study, that were either clinically or extremely obese, additionally adhered to a calorie-curbed dietetic intake and raised levels of physical activity.

It was observed that those who were administered liraglutide lost major amounts of weights as compared to those in the placebo set and on orlistat.

The weight reduction in liraglutide users was between 10lb or 4.8kg in those taking the lowest dose to 16lb or 7.2kgs in those who were given the highest dose, as compared to 6lb or 2.8kgs with the placebo set and 9lb or 4.1kgs using orlistat.

3 among 4 had more than five percent weight reduction on the highest dosage of liraglutide in comparison with the thirty percent on the placebo set and forty-four percent of those on orlistat.

Liraglutide was observed to lower blood pressure in all doses.

At the onset of the study, conducted by the group of Professor Arne Astrup and associates from the University of Copenhagen, nearly a third of the entrants from each set were having prediabetes.

The use of liraglutide lowered prediabetes by at least 84%. However, those given the shot experienced more recurring side effects of feeling nauseous, vomiting as compared to those belonging to the placebo set, but the side-effects were short-term.

Professor Astrup has stated that Liraglutide proffers a novel approach towards treating obese patients and enhancing efficiency in comparison to the presently obtainable treatments.

Its positive outcome on prediabetes indicates that it could play a significant role in obesity treatment among prediabetic persons.

However, the downside to the use of Liraglutide is that it needs to be injected and whether the long-standing usage of a medicine that could be administered solely through injection form would be appealing  enough for treating obesity, is still to be confirmed.

In reference to this form of treatment, Caroline Butler from the charity Diabetes, UK, has stated that further research is pending prior to any definite conclusions being drawn.

Popularity: 7% [?]